Capital Counsel’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
Other funds holding IDXX
Capital Counsel's IDXX Position: Q2 2026 in Review
Capital Counsel reduced its Idexx Laboratories (IDXX) stake by 0.25% in Q2 2026, selling an estimated $586K and leaving 419,151 shares worth $221M. The position accounts for 8.62% of the portfolio, ranked #4.
Capital Counsel first reported a position in IDXX in Q2 2013 and has held it in 53 quarters since. The position peaked at $321M in Q2 2021. 1,305 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Capital Counsel held 419,151 shares of Idexx Laboratories worth $221M as of Q2 2026.
- Capital Counsel sold 1,044 Idexx Laboratories shares in Q2 2026, an estimated $586K.
- Idexx Laboratories made up 8.62% of Capital Counsel's portfolio in Q2 2026, its #4 holding.
- Capital Counsel first reported a position in Idexx Laboratories in Q2 2013 and has held it in 53 quarters since.
- Capital Counsel's Idexx Laboratories position peaked at $321M in Q2 2021.
- 1,305 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Capital Counsel's 13F filing for Q2 2026, filed 12 Aug 2026.